In April 2026, 10x Genomics launched Atera, an in situ spatial biology platform unveiled at AACR that offers whole-transcriptome, single-cell–sensitive spatial analysis across fresh-frozen and FFPE ...

Immunotherapy has become a standard of care in treating high-risk, early-stage breast cancers, yet it has had limited success ...

Multivariate analyses reveal that pCR is associated with transcriptomic differences and chemotherapy type, rather than ...

Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine ...

Computational assessment identifies probe binding errors in a widely used commercial platform for spatial transcriptomics.

A robust and quantitative map links chromatin modification and gene expression of cells during zebrafish embryogenesis.

Enables Whole-Transcriptome In Situ Spatial Biology with Single-Cell Sensitivity at Scale. Debuts at AACR Annual Meeting 2026 ...

Immunotherapy has become a standard of care in treating high-risk, early-stage breast cancers, yet it has had limited success ...

Qlucore, listed on Nasdaq First North, is launching a new Qlucore Insights test (Research Use Only) specifically developed for bladder cancer samples. The software-based test delivers multiple ...

According to a new report published by Allied Market Research, the global Genomics Services Market was valued at $8.3 billion ...

Immunotherapy has become a standard of care in treating high-risk, early-stage breast cancers, yet it has had limited success ...

IRVING, Texas, April 20, 2026 /PRNewswire/ -- Caris Life Sciences (R) (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced it ...